BioSpace12m
Neurogene Drops Batten Gene Therapy Program
After failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells ...
Mitchell Kapoor Recommends Buy for Neurogene Due to Strong NGN-401 Low-Dose Safety and Potential Upside
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Neurogene (NGNE – Research Report) and keeping the price target at ...
FierceBiotech2d
Neurogene rethinks gene therapy trial after high dose leaves Rett patient in critical condition
Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that ...
BioSpace8d
Neurogene Shares Tank After Adverse Event Linked to Early-Stage Rett Syndrome Gene Therapy
Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated ...
Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial
Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing ...
pharmaphorum8d
Neurogene shares fall on Rett syndrome gene therapy data
Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...
MarketWatch2d
Neurogene Drops High-Dose Cohort of Gene-Therapy Study for Rett Syndrome
Neurogene is proceeding with a scaled-back study of its proposed NGN-401 gene therapy for the rare genetic neurological disorder Rett syndrome after a serious adverse event left a study participant ...
GlobalData on MSN8d
Neurogene’s stock sinks after adverse event with Rett syndrome gene therapy
Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...
Neurogene: Interesting CNS Disease Company, Data Coming Soon
Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.